Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Rating) General Counsel David O. Watson sold 10,000 shares of the stock in a transaction dated Wednesday, June 22nd. The shares were sold at an average price of $44.51, for a total transaction of $445,100.00. Following the completion of the sale, the general counsel now owns 115,569 shares of the company’s stock, valued at approximately $5,143,976.19. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Apellis Pharmaceuticals stock traded up $3.02 during mid-day trading on Thursday, reaching $47.00. The company’s stock had a trading volume of 1,031,467 shares, compared to its average volume of 1,063,929. Apellis Pharmaceuticals, Inc. has a 12-month low of $27.50 and a 12-month high of $73.00. The company has a quick ratio of 8.58, a current ratio of 8.85 and a debt-to-equity ratio of 0.41. The firm’s fifty day moving average price is $43.83 and its two-hundred day moving average price is $44.95.
Apellis Pharmaceuticals (NASDAQ:APLS – Get Rating) last released its quarterly earnings data on Wednesday, May 4th. The company reported ($1.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.07). Apellis Pharmaceuticals had a negative net margin of 866.81% and a negative return on equity of 607.37%. During the same quarter in the previous year, the business earned ($2.32) earnings per share. On average, analysts predict that Apellis Pharmaceuticals, Inc. will post -5.56 earnings per share for the current year.
APLS has been the subject of several analyst reports. The Goldman Sachs Group decreased their price objective on shares of Apellis Pharmaceuticals from $94.00 to $84.00 and set a “buy” rating for the company in a research note on Tuesday, May 24th. Credit Suisse Group increased their price objective on shares of Apellis Pharmaceuticals to $49.00 in a research note on Friday, May 20th. Stifel Nicolaus assumed coverage on shares of Apellis Pharmaceuticals in a research note on Thursday, June 16th. They issued a “buy” rating for the company. Raymond James decreased their price target on shares of Apellis Pharmaceuticals from $114.00 to $102.00 in a research note on Thursday, May 5th. Finally, Citigroup restated a “focus list” rating and set a $81.00 price target on shares of Apellis Pharmaceuticals in a research note on Thursday, March 17th. One analyst has rated the stock with a sell rating, two have given a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $69.64.
About Apellis Pharmaceuticals (Get Rating)
Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.
- Get a free copy of the StockNews.com research report on Apellis Pharmaceuticals (APLS)
- It’s A Comfortable Time To Buy Steelcase
- Worthington Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
- NXP Semiconductors: Strong Earnings & New Microcontrollers for Electric Vehicles
- Lithium Stocks Are Offering Unprecedented Opportunity To Investors
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.